Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P. Zuco V, et al. Among authors: cominetti d. Biochem Pharmacol. 2015 Mar 15;94(2):79-90. doi: 10.1016/j.bcp.2015.01.002. Epub 2015 Jan 16. Biochem Pharmacol. 2015. PMID: 25600908
Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I, Zunino F. Cassinelli G, et al. Among authors: cominetti d. Biochem Pharmacol. 2013 May 15;85(10):1424-32. doi: 10.1016/j.bcp.2013.02.023. Epub 2013 Mar 1. Biochem Pharmacol. 2013. PMID: 23466421
Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F, Zaffaroni N, Perego P. Gatti L, et al. Among authors: cominetti d. J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17. J Pharmacol Exp Ther. 2014. PMID: 24345465
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Cassinelli G, Zuco V, Petrangolini G, De Cesare M, Tortoreto M, Lanzi C, Cominetti D, Zaffaroni N, Orlandi A, Passeri D, Meco D, Di Francesco AM, Riccardi R, Bucci F, Pisano C, Zunino F. Cassinelli G, et al. Among authors: cominetti d. Biochem Pharmacol. 2012 Jul 15;84(2):163-71. doi: 10.1016/j.bcp.2012.04.005. Epub 2012 Apr 13. Biochem Pharmacol. 2012. PMID: 22525722
Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, Borrello MG, Zaffaroni N, Cassinelli G, Lanzi C. Lopergolo A, et al. Among authors: cominetti d. J Clin Endocrinol Metab. 2014 Feb;99(2):498-509. doi: 10.1210/jc.2013-2574. Epub 2013 Nov 25. J Clin Endocrinol Metab. 2014. PMID: 24276455
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
Gatti L, De Cesare M, Ciusani E, Corna E, Arrighetti N, Cominetti D, Belvisi L, Potenza D, Moroni E, Vasile F, Lecis D, Delia D, Castiglioni V, Scanziani E, Seneci P, Zaffaroni N, Perego P. Gatti L, et al. Among authors: cominetti d. Mol Pharm. 2014 Jan 6;11(1):283-93. doi: 10.1021/mp4004578. Epub 2013 Nov 27. Mol Pharm. 2014. PMID: 24256025
Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
De Cesare M, Lauricella C, Veronese SM, Cominetti D, Pisano C, Zunino F, Zaffaroni N, Zuco V. De Cesare M, et al. Among authors: cominetti d. Clin Cancer Res. 2014 Feb 15;20(4):995-1006. doi: 10.1158/1078-0432.CCR-13-1684. Epub 2013 Dec 10. Clin Cancer Res. 2014. PMID: 24327272
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Gatti L, Sevko A, De Cesare M, Arrighetti N, Manenti G, Ciusani E, Verderio P, Ciniselli CM, Cominetti D, Carenini N, Corna E, Zaffaroni N, Rodolfo M, Rivoltini L, Umansky V, Perego P. Gatti L, et al. Among authors: cominetti d. Oncotarget. 2014 Jun 30;5(12):4516-28. doi: 10.18632/oncotarget.2065. Oncotarget. 2014. PMID: 24980831 Free PMC article.
21 results